Clearstead Trust’s Novartis NVS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $86.2K | Hold |
550
| – | – | 0.01% | 265 |
|
|
2026
Q1 | $84K | Sell |
550
-146
| -21% | -$22.4K | 0.01% | 261 |
|
|
2025
Q4 | $96K | Hold |
696
| – | – | 0.02% | 259 |
|
|
2025
Q3 | $89.3K | Sell |
696
-124
| -15% | -$15.1K | 0.02% | 256 |
|
|
2025
Q2 | $99.2K | Buy |
820
+100
| +14% | +$11.3K | 0.02% | 244 |
|
|
2025
Q1 | $80.3K | Buy |
720
+200
| +38% | +$21.3K | 0.02% | 228 |
|
|
2024
Q4 | $50.6K | Buy |
+520
| New | +$55.5K | 0.01% | 260 |
|
|
2024
Q2 | – | Sell |
-269
| Closed | -$26K | – | 440 |
|
|
2024
Q1 | $26K | Buy |
269
+114
| +74% | +$11.7K | 0.01% | 287 |
|
|
2023
Q4 | $15.7K | Buy |
+155
| New | +$15K | ﹤0.01% | 311 |
|
|
2023
Q2 | – | Sell |
-2,060
| Closed | -$190K | – | 398 |
|
|
2023
Q1 | $190K | Sell |
2,060
-15
| -0.7% | -$1.31K | 0.06% | 136 |
|
|
2022
Q4 | $189K | Sell |
2,075
-100
| -5% | -$8.42K | 0.06% | 134 |
|
|
2022
Q3 | $166K | Buy |
2,175
+100
| +5% | +$8.29K | 0.06% | 140 |
|
|
2022
Q2 | $176K | Hold |
2,075
| – | – | 0.13% | 82 |
|
|
2022
Q1 | $182K | Hold |
2,075
| – | – | 0.12% | 90 |
|
|
2021
Q4 | $182K | Hold |
2,075
| – | – | 0.11% | 95 |
|
|
2021
Q3 | $170K | Hold |
2,075
| – | – | 0.11% | 96 |
|
|
2021
Q2 | $189K | Hold |
2,075
| – | – | 0.12% | 92 |
|
|
2021
Q1 | $177K | Hold |
2,075
| – | – | 0.13% | 85 |
|
|
2020
Q4 | $196K | Hold |
2,075
| – | – | 0.12% | 96 |
|
|
2020
Q3 | $180K | Hold |
2,075
| – | – | 0.14% | 87 |
|
|
2020
Q2 | $181K | Hold |
2,075
| – | – | 0.15% | 89 |
|
|
2020
Q1 | $171K | Hold |
2,075
| – | – | 0.15% | 90 |
|
|
2019
Q4 | $196K | Hold |
2,075
| – | – | 0.14% | 98 |
|
|
2019
Q3 | $180K | Hold |
2,075
| – | – | 0.14% | 96 |
|
|
2019
Q2 | $189K | Sell |
2,075
-241
| -10% | -$20.4K | 0.15% | 97 |
|
|
2019
Q1 | $200K | Hold |
2,316
| – | – | 0.17% | 94 |
|
|
2018
Q4 | $178K | Hold |
2,316
| – | – | 0.17% | 98 |
|
|
2018
Q3 | $179K | Hold |
2,316
| – | – | 0.14% | 96 |
|
|
2018
Q2 | $157K | Hold |
2,316
| – | – | 0.14% | 102 |
|
|
2018
Q1 | $168K | Hold |
2,316
| – | – | 0.14% | 97 |
|
|
2017
Q4 | $174K | Sell |
2,316
-9,781
| -81% | -$738K | 0.12% | 110 |
|
|
2017
Q3 | $931K | Hold |
12,097
| – | – | 0.69% | 51 |
|
|
2017
Q2 | $899K | Hold |
12,097
| – | – | 0.71% | 48 |
|
|
2017
Q1 | $805K | Hold |
12,097
| – | – | 0.67% | 48 |
|
|
2016
Q4 | $799K | Buy |
+12,097
| New | +$785K | 0.72% | 43 |
|
Other funds holding NVS
Clearstead Trust's NVS Position: Q2 2026 in Review
Clearstead Trust held its Novartis (NVS) position steady in Q2 2026 at 550 shares worth $86.2K. The position accounts for 0.01% of the portfolio, ranked #265.
Clearstead Trust first reported a position in NVS in Q4 2016 and has held it in 35 quarters since. The position peaked at $931K in Q3 2017. 1,611 funds tracked by Wall St. Rank hold NVS as of Q2 2026.
- Clearstead Trust held 550 shares of Novartis worth $86.2K as of Q2 2026.
- Clearstead Trust left its Novartis share count unchanged in Q2 2026.
- Novartis made up 0.01% of Clearstead Trust's portfolio in Q2 2026, its #265 holding.
- Clearstead Trust first reported a position in Novartis in Q4 2016 and has held it in 35 quarters since.
- Clearstead Trust's Novartis position peaked at $931K in Q3 2017.
- 1,611 funds tracked by Wall St. Rank held Novartis as of Q2 2026.
Based on Clearstead Trust's 13F filing for Q2 2026, filed 6 Aug 2026.